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Background
Since the advent of non-invasive methods for liver fibro-
sis assessment, liver biopsy has been increasingly replaced
with liver stiffness measurements or with computed
scores based on serum biomarkers, particularly for moni-
toring viral infections such as HBV [1] or HCV [2,3].
Methods
We performed a screening study using FibroMeter (Echo-
sens, Paris) to determine the stage of fibrosis and the
necroinflammatory status in a cohort of patients with
chronic HBV and HCV infection under surveillance in a
tertiary care hospital in Bucharest, Romania.
Results
We analyzed data from 87 patients, 68 (78.2%) of which
had chronic HBV infection and 19 (21.8%), chronic HCV
infection. The median age was 44.9 ± 15.0 (range 17-75).
The mean body mass index (BMI) was 26.0 ± 3.6 in the
HBV group and 26.7 ± 3.2 in the HCV group. Overall,
36 patients (41.4%) had normal BMI, another 36 (41.4%)
had a BMI equivalent for overweight status, and 15
(17.2%) had grade I obesity.
The distribution of FibroMeter results was: F0-F1: 8
(9.2%), F1: 2 (2.3%), F1-F2: 43 (49.4%), F2: 11 (12.6%), F2-
F3: 8 (9.2%), F3: 7 (8.0%), F3-F4: 8 (9.2%). The distribution
of the necroinflammatory activity was: A0-A1: 16 (18.4%),
A1-A2: 52 (59.8%), A2-A3: 19 (21.8%). We identified no
statistically significant differences between patients with
HBV and HCV regarding mean fibrosis scores (p = 0.476)
or mean necroinflammatory activity scores (p = 0.681).
Conclusion
The patients included in this study had varied ages and
characteristics. FibroMeter classified most of them as
F1-F2 but descriptive data should be interpreted in clini-
cal context and potential confounding factors should be
identified on a case-by-case basis.
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